Period of time： 2014年1期
Publisher： Informa Healthcare
Founded in： 2002
Total resources： 54
ISSN： 1474-0338
Subject： R9 Pharmacy
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Expert Opinion on Drug Safety,volume 2,issue 1
Menu
Access to resources
Recommend
Safety and efficacy of meningococcal group C conjugate vaccines
By Rüggeberg Jens,Heath Paul T in (2003)
Expert Opinion on Drug Safety,volume 2,issue 1 , Vol. 2, Iss. 1, 2003-01 , pp.Neuroleptic malignant syndrome induced by atypical antipsychotics
Expert Opinion on Drug Safety,volume 2,issue 1 , Vol. 2, Iss. 1, 2003-01 , pp.Efficacy and safety of midodrine in the treatment of dialysis-associated hypotension
Expert Opinion on Drug Safety,volume 2,issue 1 , Vol. 2, Iss. 1, 2003-01 , pp.Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
By Westerhout Cynthia M,Boersma Eric in (2003)
Expert Opinion on Drug Safety,volume 2,issue 1 , Vol. 2, Iss. 1, 2003-01 , pp.Cardiotoxic effects of anthracycline–taxane combinations
By Perotti Antonella,Cresta Sara,Grasselli Giacomo,Capri Giuseppe,Minotti Giorgio,Gianni Luca in (2003)
Expert Opinion on Drug Safety,volume 2,issue 1 , Vol. 2, Iss. 1, 2003-01 , pp.Safety issues surrounding the use of aromatase inhibitors in breast cancer
By Jackson J,Miller WR,Dixon JM in (2003)
Expert Opinion on Drug Safety,volume 2,issue 1 , Vol. 2, Iss. 1, 2003-01 , pp.Safety of low molecular weight heparins in the treatment of venous thromboembolism
By Bernardi Enrico,Prandoni Paolo in (2003)
Expert Opinion on Drug Safety,volume 2,issue 1 , Vol. 2, Iss. 1, 2003-01 , pp.4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
By Nolan David,Christiansen Frank in (2003)
Expert Opinion on Drug Safety,volume 2,issue 1 , Vol. 2, Iss. 1, 2003-01 , pp.